Doctors Should Wait To Treat Patients After Transplant Surgery, Study RevealsEditor's Choice
Main Category: Transplants / Organ Donations
Article Date: 26 Aug 2012 - 1:00 PST
Ad For Health Professionals
Doctors Should Wait To Treat Patients After Transplant Surgery, Study Reveals
|Patient / Public:|
A new study, published in the Journal of the American Society of Nephrology (JASN), reveals that Cytomegalovirus (CMV), which is the most common virus to infect organ transplant patients, should not be treated immediately after surgery - and waiting until the patients reach a certain point of recovery is better than prophylactically treating every patient.
CMV is the most common infection among organ transplant patients. These patients are extremely sensitive to infections because their immune systems are weak due to the immunosuppressive medications the patients are prescribed prior to surgery. The risk of organ rejection, heart complications, and other infections comes with CMV.
In order to avoid CMV doctors use one of two methos:
- Universal antiviral prophylaxis - All patients receive antiviral medications for many months after they undergo surgery. These medications may include; valacyclovir, valganciclovir, and ganciclovir.
- Pre-emptive therapy - Doctors monitor the patients' recovery very closely using sensitive laboratory methods. Antiviral treatment is only given to patients who are experiencing significant viral counts, in order to avoid serious symptoms.
Three years later, the researchers found:
- 6% of patients in the pre-emptive group and 9% receiving prophylaxis developed CMV.
- The Prophylaxis group was 2.5 times more likely to have moderate or severe scaring of the kidneys.
- The prophylaxis group also had much higher expression of genes prevalent in scaring of the kidneys.
- CMV prevalence in both groups was relatively the same. However, pre-emptive treatment resulted in a 4 year survival improvement among the transplanted organs, a difference of 92% to 74%.
Dr. Reischig concluded:
"In the view of short-term trial results, which favor CMV prophylaxis over pre-emptive strategy because of lower risk of acute rejection, we expected a translation of presumed benefit of prophylaxis to the long-term post-transplant period. In fact, we discovered that the opposite is true."
Written by Christine Kearney
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
Tomas Reischig, Petra Hribova, Pavel Jindra, Ondrej Hes‖, Mirko Bouda, Vladislav Treska and Ondrej Viklicky
JASN, August 2012, doi:10.1681/ASN.2012010100
19 Jun. 2013. <http://www.medicalnewstoday.com/articles/249459.php>
Please note: If no author information is provided, the source is cited instead.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.